| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3206656 | Journal of the American Academy of Dermatology | 2012 | 7 Pages |
Abstract
Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necrosis factor-alfa activity. Leflunomide has demonstrated usefulness in treating cutaneous psoriasis along with other dermatologic and rheumatologic conditions.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Alan S. Boyd,